Navigation Links
Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of ,Alex Leaf Distinguished Scientist Award

DHA omega-3 innovator and maker of the life’sDHA™ brand, Martek Biosciences Corporation (NASDAQ: MATK) announced today that Norman Salem, Jr., Ph.D., Martek’s vice president of research and chief scientific officer, has been selected as the recipient of the Alex Leaf Distinguished Scientist Award for 2010.

Columbia, Md. (Vocus) -- DHA omega-3 innovator and maker of the life’sDHA™ brand, Martek Biosciences Corporation (NASDAQ: MATK) announced today that Norman Salem, Jr., Ph.D., Martek’s vice president of research and chief scientific officer, has been selected as the recipient of the Alex Leaf Distinguished Scientist Award for 2010. The Alex Leaf Award is presented by the International Society for the Study of Fatty Acids and Lipids (ISSFAL) to scientists in recognition of excellence in the research of the health effects of dietary fats, oils and lipids. ISSFAL is the foremost international scientific society dealing exclusively with the health impact of dietary lipids. Dr. Salem was presented the award at the 2010 ISSFAL meeting held May 29 - June 2, in the Netherlands.

“We congratulate Dr. Salem on this honor and recognize him both for his contributions to his field and for his outstanding leadership of Martek’s ongoing research efforts,” said Steve Dubin, Martek CEO.

Dr. Salem is widely recognized as one of the world's leading researchers on docosahexaenoic acid (DHA) and the functions of polyunsaturated fatty acids and lipids. He joined Martek in 2008 after 30 years with The National Institutes of Health (“NIH”) where he led the prestigious Laboratory of Membrane Biochemistry and Biophysics. His scientific work while at NIH included a focus on the role of DHA in neural development as well as on how DHA is made in the body and incorporated into the brain and other organs.

In his role at Martek, Dr. Salem is responsible for leading the company’s clinical research, discovery, microbial biotechnology, and analytical sciences groups and supports the efforts of scientific affairs and medical research. Under his leadership, Martek has made significant progress in expanding the company’s pipeline of new products based on its proprietary microbial biotechnology platform.

Dr. Salem received his B.S. degree in physics from Miami University of Ohio and his Ph.D. in neurobiology from the University of Rochester School of Medicine. During his career, Dr. Salem has published over 200 research articles and book chapters. He was the 2002 recipient of the Supelco/Nicholas Pelick Research Award from the American Oil Chemists Society, which recognizes outstanding original research in fats, oils, lipid chemistry, or biochemistry.

Martek Biosciences Corporation (NASDAQ: MATK) is a leader in the innovation, development, production and sales of high-value products from microbial sources that promote health and wellness through nutrition. The company is the world’s leading provider of algal DHA omega-3 with its flagship product, life'sDHA, a sustainable and vegetarian source of algal DHA omega-3 important for brain, heart and eye health throughout life, for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA™ (arachidonic acid), an omega-6 fatty acid, for use in infant formula and growing-up milks. Additionally, Martek's subsidiary, Amerifit Brands, develops, markets and distributes branded consumer health and wellness products in major mass, club, drug, grocery and specialty stores and holds leading brand positions in all of its key product categories. For more information on Martek Biosciences, visit For a complete list of life'sDHA™ or life'sARA™ products, visit For more information about Amerifit Brands, visit

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2009 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

Cassie France-Kelly
Public Relations
(443) 542-2116


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
2. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
4. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
5. Crown Works Dental Laboratory hosts CE Course by Dr. Damon C. Adams, Editor -In -Chief of Dentistry Today
6. Resveratrol Supplement Company RevGenetics Welcomes New Chief Science Officer
7. iSirona Appoints Chief Quality and Regulatory Officer to Oversee Quality Initiatives
8. SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer
9. Pollogen Ltd. Names Ohad Goren Chief Executive Officer
10. Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer
11. HCMS Group LLC Names Mick Simon Chief Operating Officer
Post Your Comments:
Related Image:
Martek Biosciences Chief Scientific Officer, Dr. Norman Salem, 2010 Recipient of ,Alex Leaf Distinguished Scientist Award 
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with ... for the primary prevention of cardiovascular diseases during the 15th Annual Women’s ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology: